These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 14690537)

  • 1. Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation.
    Dehmer T; Heneka MT; Sastre M; Dichgans J; Schulz JB
    J Neurochem; 2004 Jan; 88(2):494-501. PubMed ID: 14690537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease.
    Breidert T; Callebert J; Heneka MT; Landreth G; Launay JM; Hirsch EC
    J Neurochem; 2002 Aug; 82(3):615-24. PubMed ID: 12153485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protective action of neuronal nitric oxide synthase inhibitor in the MPTP mouse model of Parkinson's disease.
    Watanabe Y; Kato H; Araki T
    Metab Brain Dis; 2008 Mar; 23(1):51-69. PubMed ID: 18030609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protective effects of neuronal nitric oxide synthase inhibitor in mouse brain against MPTP neurotoxicity: an immunohistological study.
    Watanabe H; Muramatsu Y; Kurosaki R; Michimata M; Matsubara M; Imai Y; Araki T
    Eur Neuropsychopharmacol; 2004 Mar; 14(2):93-104. PubMed ID: 15013024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deficiency of inducible nitric oxide synthase protects against MPTP toxicity in vivo.
    Dehmer T; Lindenau J; Haid S; Dichgans J; Schulz JB
    J Neurochem; 2000 May; 74(5):2213-6. PubMed ID: 10800968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combining nitric oxide release with anti-inflammatory activity preserves nigrostriatal dopaminergic innervation and prevents motor impairment in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.
    L'Episcopo F; Tirolo C; Caniglia S; Testa N; Serra PA; Impagnatiello F; Morale MC; Marchetti B
    J Neuroinflammation; 2010 Nov; 7():83. PubMed ID: 21092260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phytic acid attenuates inflammatory responses and the levels of NF-κB and p-ERK in MPTP-induced Parkinson's disease model of mice.
    Lv Y; Zhang Z; Hou L; Zhang L; Zhang J; Wang Y; Liu C; Xu P; Liu L; Gai X; Lu T
    Neurosci Lett; 2015 Jun; 597():132-6. PubMed ID: 25929185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The PPARgamma agonist pioglitazone is effective in the MPTP mouse model of Parkinson's disease through inhibition of monoamine oxidase B.
    Quinn LP; Crook B; Hows ME; Vidgeon-Hart M; Chapman H; Upton N; Medhurst AD; Virley DJ
    Br J Pharmacol; 2008 May; 154(1):226-33. PubMed ID: 18332857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of p38 MAPK in the substantia nigra leads to nuclear translocation of NF-kappaB in MPTP-treated mice: implication in Parkinson's disease.
    Karunakaran S; Ravindranath V
    J Neurochem; 2009 Jun; 109(6):1791-9. PubMed ID: 19457134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of nuclear transcription factor kappa B (NF-kappaB) for MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahyropyridine)-induced apoptosis in nigral neurons of mice.
    Aoki E; Yano R; Yokoyama H; Kato H; Araki T
    Exp Mol Pathol; 2009 Feb; 86(1):57-64. PubMed ID: 19027004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [P38 MAPK signaling pathway regulates nuclear factor-κB and inducible nitric oxide synthase expressions in the substantia nigra in a mouse model of Parkinson's disease].
    Wang Q; Zhang H; Liu M; Zhang Z; Wei Z; Sun N; Mao T; Zhang Y
    Nan Fang Yi Ke Da Xue Xue Bao; 2014 Jul; 34(8):1176-80. PubMed ID: 25176090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuronal or inducible nitric oxide synthase (NOS) expression level is not involved in the different susceptibility to nigro-striatal dopaminergic neurotoxicity induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) between C57BL/6 and BALB/c mice.
    Ito T; Uchida K; Nakayama H
    Exp Toxicol Pathol; 2013 Jan; 65(1-2):121-5. PubMed ID: 21788124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of peroxisome proliferator-activated receptor-gamma in the substantia nigra of hemiparkinsonian nonhuman primates.
    Swanson C; Emborg M
    Neurol Res; 2014 Jul; 36(7):634-46. PubMed ID: 24620964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease.
    Schintu N; Frau L; Ibba M; Caboni P; Garau A; Carboni E; Carta AR
    Eur J Neurosci; 2009 Mar; 29(5):954-63. PubMed ID: 19245367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nitric oxide synthase inhibition and MPTP-induced toxicity in the common marmoset.
    Mackenzie GM; Jackson MJ; Jenner P; Marsden CD
    Synapse; 1997 Jul; 26(3):301-16. PubMed ID: 9183819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-inflammatory and neuroprotective effects of an orally active apocynin derivative in pre-clinical models of Parkinson's disease.
    Ghosh A; Kanthasamy A; Joseph J; Anantharam V; Srivastava P; Dranka BP; Kalyanaraman B; Kanthasamy AG
    J Neuroinflammation; 2012 Oct; 9():241. PubMed ID: 23092448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Shikonin ameliorates oxidative stress and neuroinflammation via the Akt/ERK/JNK/NF-κB signalling pathways in a model of Parkinson's disease.
    Guo L; Li Y; Li W; Qiu J; Du J; Wang L; Zhang T
    Clin Exp Pharmacol Physiol; 2022 Nov; 49(11):1221-1231. PubMed ID: 36054693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of the PPARgamma activator pioglitazone on p38 MAP kinase and IkappaBalpha in the spinal cord of a transgenic mouse model of amyotrophic lateral sclerosis.
    Shibata N; Kawaguchi-Niida M; Yamamoto T; Toi S; Hirano A; Kobayashi M
    Neuropathology; 2008 Aug; 28(4):387-98. PubMed ID: 18312546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease.
    Liberatore GT; Jackson-Lewis V; Vukosavic S; Mandir AS; Vila M; McAuliffe WG; Dawson VL; Dawson TM; Przedborski S
    Nat Med; 1999 Dec; 5(12):1403-9. PubMed ID: 10581083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroprotection by freshwater clam extract against the neurotoxin MPTP in C57BL/6 mice.
    Hsieh CC; Lin MS; Hua KF; Chen WJ; Lin CC
    Neurosci Lett; 2017 Mar; 642():51-58. PubMed ID: 28126590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.